Concerns are mounting over the safety of weight loss injections, specifically GLP-1 agonists, following the potential link of two deaths in Northern Ireland and over 500 suspected adverse drug reactions to these medications. The Medicines and Healthcare products Regulatory Agency (MHRA) has received numerous reports related to GLP-1s, with two fatal cases specifically cited: one involving Mounjaro, dubbed the 'King Kong' of fat-busting jabs, and another linked to an unidentified semaglutide medication. Common GLP-1s, including Wegovy, Ozempic, and Rybelsus (also approved for type 2 diabetes), contain semaglutide, which functions by mimicking hormones released during eating.

The MHRA emphasizes that a report of a suspected reaction does not automatically confirm causation, suggesting that underlying illnesses, concurrent conditions, or coincidental events could be responsible. The two reported deaths involved a man and a woman, aged in their 60s and 40s respectively. While the MHRA could not ascertain whether the associated medication was prescribed, purchased from a pharmacy, or obtained from an illegitimate supplier, the agency has taken proactive steps to update product information for GLP-1s.

A critical warning issued earlier this year by the MHRA highlighted the risk of severe inflammation of the pancreas, a potentially fatal condition often associated with gallstones, which is a known side effect of these injections. Consequently, the drug watchdog has updated product information for GLP-1s to underscore a